Steven Mickelsen, MD, Joins Acutus Medical as Chief Translational Science Officer
November 12 2020 - 4:02PM
Acutus Medical (Nasdaq: AFIB) today announced the appointment of
Steven Mickelsen, MD, as Chief Translational Science Officer. Dr.
Mickelsen will help guide the company’s vision to deliver the most
advanced electrophysiology therapeutic solutions on the market for
physicians and their patients. Mickelsen’s impact will further
advance the company’s commitment to innovation across its access,
diagnostic and therapy product portfolio, including researching,
developing and advancing gold-tip catheter technology for Pulsed
Field Ablation (PFA) and Radiofrequency (RF) ablation technologies.
“Acutus is committed to creating game-changing solutions and
establishing new standards of care for cardiac arrhythmia
management,” said Vince Burgess, President and CEO of Acutus
Medical. “Dr. Mickelsen’s clinical and technical expertise and
unique history pioneering the development of breakthrough
therapeutic medical devices is indispensable as we progress from
research to commercialization of important technologies such as
Pulsed Field Ablation.”
Dr. Mickelsen joins Acutus Medical following an esteemed career
practicing as a cardiac electrophysiologist at the University of
Iowa Hospitals and Clinics in Iowa City. He focuses on complex
ablation procedures and serves on faculty as Assistant Professor of
Cardiovascular Medicine and Internal Medicine, and will continue
his tenure going forward. In 2012, Dr. Mickelsen founded Farapulse,
a company devoted to the discovery of more effective treatments for
atrial fibrillation through the utilization of a pulsed electric
field system that he invented. He served as the company’s initial
President and CEO, and later as its Chief Science Officer, before
stepping down in 2016 to focus on clinical research.
“The field of arrhythmia science is evolving at a breakneck
speed. Physicians want to provide the best possible care, but we’re
often confined by the limitations of technology. Acutus is changing
that, and this is an opportunity to play a critical role delivering
advanced EP solutions to treat the entire spectrum of cardiac
arrhythmias,” said Dr. Mickelsen. “Pulsed field ablation represents
an exciting potential future for EP; I’m thrilled to join a team
that is dedicated to creating new solutions and enhancing the
possibilities for physicians and their patients.”
Dr. Mickelsen is a board-certified electrophysiologist. He
received his medical degree from the University of New Mexico
School of Medicine, was a Howard Hughes Research Scholar at the
National Institutes of Health in Bethesda, MD, and completed his
internal medicine residency and clinical research at the Mayo
Clinic. He also completed fellowships in Cardiology and Cardiac
Electrophysiology at the University of Iowa Hospitals and
Clinics.
About Acutus Medical Acutus Medical is an
arrhythmia management company focused on improving the way cardiac
arrhythmias are diagnosed and treated. Acutus is committed to
advancing the field of electrophysiology with a unique array of
products and technologies which will enable more physicians to
treat more patients more efficiently and effectively. Through
internal product development, acquisitions and global partnerships,
Acutus has established a global sales presence delivering a broad
portfolio of highly differentiated electrophysiology products that
provide its customers with a complete solution for catheter-based
treatment of cardiac arrhythmias in each of its geographic markets.
Founded in 2011, Acutus is based in Carlsbad, California.
Acutus PFA Technology is not for sale in the United States
Follow Acutus Medical on:
- Twitter: @AcutusMedical
- LinkedIn: www.linkedin.com/company/acutus-medical-inc-/
- Facebook: @AcutusMedical
US Media ContactsLevitate(260)
408-5383acutus@levitatenow.com
Acutus Medical (NASDAQ:AFIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acutus Medical (NASDAQ:AFIB)
Historical Stock Chart
From Apr 2023 to Apr 2024